Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $2.09 on Tuesday. The stock has a 50 day simple moving average of $2.00 and a 200 day simple moving average of $1.90. Aeterna Zentaris has a 52-week low of $1.36 and a 52-week high of $3.30. The firm has a market capitalization of $10.16 million, a PE ratio of -0.61 and a beta of 1.57.

Aeterna Zentaris shares are scheduled to reverse split before the market opens on Friday, May 3rd. The 1-4 reverse split was announced on Friday, May 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 3rd.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.19). The company had revenue of $0.12 million during the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.